Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.

ABSTRACT:

Importance

Greater levels of treatment resistance in major depressive disorder (MDD) are associated with lower rates of initial benefit and higher rates of relapse (lower durability).

Objective

Characterize depressive symptoms, function, and quality of life (QoL) over 24 months of adjunctive vagus nerve stimulation (VNS) in participants with markedly treatment-resistant depression.

Design

Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025.

Setting

Outpatient.

Participants

Adults with moderate-severe MDD with ≥ 4 failed antidepressant trials in the current episode, randomized to blinded, adjunctive VNS for 12 months, who subsequently received open-label, adjunctive VNS for 12 additional mon

SUBMITTER: Conway CR 

PROVIDER: S-EPMC12799215 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature